Key statistics
As of last trade PTC Therapeutics Inc (BH3:FRA) traded at 40.60, -6.45% below its 52-week high of 43.40, set on Nov 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.60 |
---|---|
High | 40.60 |
Low | 40.60 |
Bid | 40.40 |
Offer | 41.60 |
Previous close | 39.40 |
Average volume | 343.11 |
---|---|
Shares outstanding | 77.13m |
Free float | 75.32m |
P/E (TTM) | -- |
Market cap | 3.31bn USD |
EPS (TTM) | -5.94 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:11 GMT.
More ▼
Press releases
- PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
- CHMP Maintains Negative Opinion on Translarna™ Reexamination
- PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
- PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
- PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
More ▼